GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com

PMID:23328768

From GONUTS
Jump to: navigation, search
Citation

Fiorentini, C, Savoia, P, Savoldi, D, Barbon, A and Missale, C (2013) Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. Neurobiol. Dis. 54:339-48

Abstract

Prolonged l-3,4-dihydroxyphenylalanine (l-DOPA) administration, the gold standard therapy for Parkinson's disease (PD) is associated with serious motor complications, known as l-DOPA-induced dyskinesia (LID). One of the major molecular changes associated with LID is the increased activity of the extracellular signal-regulated kinases 1/2 (Erk1/2) signaling in the medium spiny neurons of the striatum induced by malfunctioning in the dopamine D1 receptor (D1R)-mediated transmission. We have previously established that in the striatum, activation of Shp-2, an intracellular tyrosine phosphatase associated with the D1R, is a requisite for the D1R to activate Erk1/2. In this study, we investigated the role of striatal D1R/Shp-2 complex in the molecular event underlying LID in the 6-OHDA-lesioned rat model of PD. We found that in hemiparkinsonian rats experiencing LID, the physiological interaction between D1R and Shp-2 in the striatum was preserved. In these animals, the chronic activation of D1R either by l-DOPA or by the selective D1R agonist SKF 38393 induced both dyskinesia and Shp-2/Erk1/2 activation. These effects were prevented by the selective D1R-antagonist SCH23390 suggesting the involvement of striatal D1R/Shp-2 complex, via Erk1/2 activation, in the molecular events underlying LID. Interestingly, we found that D1R-mediated Shp-2-Erk1/2 activation was persistently detected in the striatum of dyskinetic rats during l-DOPA washout, with a close correlation between LID severity and the extent of long term activation of both Shp-2 and Erk1/2. Taken together, our data show that in hemiparkinsonian rats developing dyskinesia, the aberrant phosphorylation of Shp-2 by D1R activation, represents an upstream molecular event leading to the persistent phosphorylation of Erk1/2 and therefore a novel therapeutic target to counteract LID development and maintenance during l-DOPA therapy.

Links

PubMed Online version:10.1016/j.nbd.2013.01.005

Keywords

Adrenergic Agents/toxicity; Animals; Antiparkinson Agents/pharmacology; Blotting, Western; Dyskinesia, Drug-Induced/metabolism; Immunoprecipitation; Levodopa/pharmacology; MAP Kinase Signaling System/physiology; Male; Oxidopamine/toxicity; Parkinsonian Disorders/metabolism; Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism; Rats; Rats, Wistar; Receptors, Dopamine D1/metabolism

Significance

Annotations

Gene product Qualifier GO Term Evidence Code with/from Aspect Extension Notes Status

RAT:PTN11

enables

GO:0031748: D1 dopamine receptor binding

ECO:0000353: physical interaction evidence used in manual assertion

RGD:2518

F

Seeded From UniProt

complete

RAT:DRD1

enables

GO:0019903: protein phosphatase binding

ECO:0000353: physical interaction evidence used in manual assertion

RGD:3447

F

Seeded From UniProt

complete

Notes

See also

References

See Help:References for how to manage references in GONUTS.